The massive YORVIPATH revenue beat and first-ever operating profit mark a fundamental inflection point. The convertible note conversion eliminates a large overhang and the PRV sale adds cash. Watch for YUVIWEL enrollment trajectory and EU regulatory decision in Q4 2026 as the next catalysts. The oncology discontinuation is a minor negative but strategically sound.
ASND drugs
ASND drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $246.14entry
- T+1 · 6mo ago −3.04%α −3.87% · $238.66
- T+5 · 6mo ago −1.04%α −2.54% · $243.58
- T+20 · 5mo ago −11.92%α −15.06% · $216.79
- T+60 · 3mo ago −1.09%α −4.93% · $243.45
Price Chart
How similar events traded
Executive Summary
Ascendis Pharma reported Q1 2026 revenue of €247M (up 144% YoY from €101M), driven by YORVIPATH sales of €197M. The company achieved its first-ever operating profit of €25M (vs. a €104M loss in Q1 2025) and a non-IFRS operating profit of €55M. Net profit of €629M included a €679M deferred tax asset recognition; non-IFRS net profit was €18M. Subsequent events include the conversion of $575M convertible notes into 3.6M ordinary shares and a $187.5M PRV sale agreement.
Key Facts
- Q1 2026 total revenue €247M vs €101M YoY (+144%)
- YORVIPATH revenue €197M vs €45M YoY (+341%)
- SKYTROFA revenue €44M vs €51M YoY (-14%)
- Operating profit €25M vs loss of €104M YoY
- Non-IFRS operating profit €55M vs loss of €79M YoY
- Non-IFRS net profit €18M vs loss of €73M YoY
- Net profit €629M includes €679M deferred tax asset recognition
- Cash and equivalents €573M as of March 31, 2026
- Converted all $575M 2.25% convertible notes due 2028 into 3,635,813 ordinary shares on May 6, 2026
- Agreed to sell Rare Pediatric Disease PRV for $187.5M cash
- YUVIWEL launched in U.S. with >60 patient enrollments as of May 1, 2026
- Discontinued internal development of TransCon IL-2/oncology program
Financial Impact
Revenue more than doubled YoY to €247M; operating income swung from -€104M to +€25M; non-IFRS operating profit margin 22.4%; $187.5M PRV sale and $575M convertible note conversion strengthen balance sheet
Risk Factors
- SKYTROFA revenue declining 14% YoY signals potential market share loss
- SG&A expenses rose 44% YoY to €145M, pressuring margins
- Operating cash flow still negative at -€8M despite revenue growth
- Dilution from convertible note conversion adds 3.6M shares
- EU approval for YUVIWEL not guaranteed and could be delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-210386 |
| Document: d121855d6k.htm | 0001193125-26-210386 |
| Document: 0001193125-26-210386-index-headers.html | 0001193125-26-210386 |
| Document: 0001193125-26-210386-index.html | 0001193125-26-210386 |
| Document: 0001193125-26-210386.txt | 0001193125-26-210386 |
Track record
41 reports on ASND
14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $267.07 Now $271.73 +1.74% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 20269d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers